



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
23.01.2008 Bulletin 2008/04

(43) Date of publication A2:
12.12.2007 Bulletin 2007/50

(21) Application number: **07117575.6**

(22) Date of filing: **10.02.2003**

(51) Int Cl.:
C07D 213/82 (2006.01) **C07D 401/14** (2006.01)
C07D 417/12 (2006.01) **C07D 405/12** (2006.01)
C07D 409/12 (2006.01) **C07D 401/12** (2006.01)
A61K 31/4418 (2006.01) **A61K 31/4427** (2006.01)
A61P 25/00 (2006.01) **A61P 11/00** (2006.01)
A61P 29/00 (2006.01) **A61P 19/00** (2006.01)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR
Designated Extension States:
LT LV RO

(30) Priority: **12.02.2002 GB 0203301**
31.10.2002 GB 0225385

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
03704769.3 / 1 474 395


(71) Applicant: **SmithKline Beecham Corporation**
Philadelphia, PA 19101 (US)

(72) Inventors:
• **Aston, Nicola, Mary**
Stevenage, Hertfordshire SG1 2NY (GB)
• **Bamborough, Paul**
Stevenage, Hertfordshire SG1 2NY (GB)
• **Walker, Ann, Louise**
Stevenage, Hertfordshire SG1 2NY (GB)

(74) Representative: **Shore, Andrew David et al**
GlaxoSmithKline
Corporate Intellectual Property (CN 925.1)
980 Great West Road
Brentford,
Middlesex TW8 9GS (GB)

(54) **Nicotinamide derivates useful as P38 inhibitors**

(57) Compounds of formula (I):



(I)

are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 63 of the European Patent Convention EP 07 11 7575
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	WO 01/70695 A (EVINDAR GHOTAS ;BEMIS GUY (US); VERTEX PHARMA (US); SALITURO FRANC) 27 September 2001 (2001-09-27) * the whole document * -----	1-13	INV. C07D213/82 C07D401/14 C07D417/12 C07D405/12 C07D409/12 C07D401/12 A61K31/4418 A61K31/4427 A61P25/00 A61P11/00 A61P29/00 A61P19/00
			TECHNICAL FIELDS SEARCHED (IPC)
			C07D A61K A61P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
The Hague		23 November 2007	Bosma, Peter
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons			
& : member of the same patent family, corresponding document			

2
EPO FORM 1503 03.82 (P04E07)



Although claim 10 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
